Dexamethasone nanomedicines for COVID-19

Twan Lammers (Corresponding author), Alexandros Marios Sofias, Roy van der Meel, Raymond M. Schiffelers, Gert Storm, Frank Tacke, Steffen Koschmieder, Tim H. Bruemmendorf, F. Kiessling, Josbert M. Metselaar (Corresponding author)

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

75 Citations (Scopus)
4 Downloads (Pure)


Nano-formulating dexamethasone, and administering it via intravenous injection or inhalation, may help to improve anti-COVID-19 treatment efficacy by targeting the potent corticosteroid drug to hyper-activated immune cells, by potentiating its anti-oedema activity and by exploiting its anti-fibrotic effects.
Original languageEnglish
Pages (from-to)622-624
Number of pages3
JournalNature Nanotechnology
Issue number8
Publication statusPublished - 3 Aug 2020


Dive into the research topics of 'Dexamethasone nanomedicines for COVID-19'. Together they form a unique fingerprint.

Cite this